Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Register for free with vnonline.co.uk to gain unlimited access to news, resources, jobs and much more!



Click here to become a member







Log in to vnonline

Forgot your password?

Posted: 2019-09-26

Agreement to develop E. coli O157:H7 vaccine
Researchers at work on the project in the Roslin Institute
Collaborative research enters commercial phase

Roslin Technologies has signed an agreement with animal sciences research establishments Moredun Research Institute, Scotland’s Rural College and the Roslin Institute at the University of Edinburgh, to fund the commercial development of an E. coli O157:H7 vaccine for cattle, which it is claimed will prevent illness in humans.

E. coli O157:H7 is a pathogenic bacterium of cattle that can cause life-threatening food-borne illness in humans through the consumption of contaminated products, such as dairy products and meat. Despite efforts to reduce contamination of food, E. coli O157:H7 causes one to 10 cases per 100,000 people, with certain countries having clusters of more virulent strains – notably the UK, USA, Argentina and Sweden.
 
The experimental vaccine has been developed to limit E. coli O157:H7 shedding from – and transmission between – cattle. Although the bacteria do not harm cattle, farmers will be encouraged to vaccinate animals against infection with this new vaccine. Early results have indicated that this vaccine may be more effective than other previous attempts and have a greater impact in reducing human exposure and infection.

The project team has been led by Dr Simon Wheeler COO of Roslin Technologies, with significant input from the principal investigators, Professor David Gally from Roslin Institute and Dr Tom McNeilly from Moredun Research Institute, who have been doing the fundamental research necessary to really understand whether the vaccine works and the essential science behind it.

Under the new agreement, Roslin Technologies will perform a two-step validation trial from May  to September 2020 in Nebraska, USA. The field trials will examine ‘super-shedding’ in cattle to discover whether the vaccine prevents shedding of the bacteria and is viable for commercial use.
 
The background research was funded  in part by UK agencies Defra (Department for Environment, Food & Rural Affairs), BBSRC (Biotechnology and Biological Sciences Research Council, FSA/FSS (Food Standards Agency/Food Standards Scotland), and other commercial partners. This valuable contribution is recognised by the project team.



Become a member
or log in to add this story to your CPD history